Boosting both endocannabinoids simultaneously reduced migraine-like pain in rats
Dual inhibition of both endocannabinoid-degrading enzymes (FAAH and MAGL) reduced migraine-like pain and neuroinflammatory markers in rats, likely through CB1 receptor activation.
Quick Facts
What This Study Found
The dual FAAH/MAGL inhibitor JZL195 significantly reduced nitroglycerin-induced trigeminal hyperalgesia and pain-associated behavior, likely via CB1 receptors. It decreased CGRP and cytokine gene expression in both central (cervical spinal cord) and peripheral (trigeminal ganglion) structures, plus reduced CGRP serum levels. However, it did not improve nitroglycerin-induced hypomotility or anxiety.
Key Numbers
JZL195 reduced trigeminal hyperalgesia and pain behavior via CB1; decreased CGRP gene expression in cervical spinal cord and trigeminal ganglion; reduced CGRP serum levels; decreased cytokine gene expression centrally and peripherally; no effect on hypomotility or anxiety
How They Did This
Rats received nitroglycerin to induce migraine-like features, then JZL195 (dual FAAH/MAGL inhibitor). Assessed orofacial formalin test (trigeminal pain), open field (activity/anxiety), CGRP serum levels, and gene expression of CGRP and cytokines in spinal cord and trigeminal ganglion.
Why This Research Matters
Individual FAAH or MAGL inhibitors have shown promise for migraine. Dual inhibition may provide synergistic pain relief by boosting both anandamide and 2-AG simultaneously, with broader anti-inflammatory effects across central and peripheral pain pathways.
The Bigger Picture
The simultaneous reduction of CGRP (the target of current migraine antibody drugs) and inflammatory cytokines across multiple pain processing sites suggests endocannabinoid boosting could offer a multi-target approach to migraine treatment.
What This Study Doesn't Tell Us
Acute animal model of migraine, not chronic. Dual inhibition may have more side effects than selective inhibition. CB1-mediated effects could include psychoactive properties. Does not address tolerability or abuse potential.
Questions This Raises
- ?Would dual endocannabinoid enhancement be tolerable in humans given CB1-mediated effects?
- ?How does this approach compare to existing CGRP-targeting migraine treatments?
Trust & Context
- Key Stat:
- Dual FAAH/MAGL inhibition reduced both pain and CGRP in central and peripheral sites
- Evidence Grade:
- Well-designed preclinical study with multiple endpoints, but limited by acute model and male rats only.
- Study Age:
- Published in 2021.
- Original Title:
- Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine.
- Published In:
- Cells, 10(10) (2021)
- Authors:
- Greco, Rosaria, Demartini, Chiara, Francavilla, Miriam, Zanaboni, Anna Maria, Tassorelli, Cristina
- Database ID:
- RTHC-03172
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How could endocannabinoids help migraines?
The study boosted both main endocannabinoids (anandamide and 2-AG) simultaneously, which reduced migraine-like pain and lowered CGRP, the same molecule targeted by current migraine antibody drugs. The endocannabinoid approach also reduced inflammatory cytokines.
Is this the same as using cannabis for migraines?
Not exactly. This approach boosts the body's own endocannabinoids rather than introducing external cannabinoids. It may offer more targeted effects, though the CB1 receptor involvement means some cannabis-like effects are possible.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03172APA
Greco, Rosaria; Demartini, Chiara; Francavilla, Miriam; Zanaboni, Anna Maria; Tassorelli, Cristina. (2021). Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine.. Cells, 10(10). https://doi.org/10.3390/cells10102543
MLA
Greco, Rosaria, et al. "Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine.." Cells, 2021. https://doi.org/10.3390/cells10102543
RethinkTHC
RethinkTHC Research Database. "Dual Inhibition of FAAH and MAGL Counteracts Migraine-like P..." RTHC-03172. Retrieved from https://rethinkthc.com/research/greco-2021-dual-inhibition-of-faah
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.